.png)
Melanoma Market By Type (Acral Lentigious, Lentigo Maglina, Superficial Spreading, Nodular and Others Type), Gender (Female and Male), Treatment (Surgery, Radiation Therapy, Immunotherapy, Chemotherapy, Biologic Therapy and Others Treatment), Diagnosis (Ugly Duckling, Biopsy, ABCDE and Other Diagnosis) and End User (Clinics, Laboratories, Research Centers, Hospitals and Pharmaceutical Companies) - Global Industry Analysis And Forecast To 2027
Published On : September 2018 Pages : 180 Category: Pharma & Healthcare Report Code : HC091266
SEGMENTS & REGIONS:
- By Type: Acral Lentigious, Lentigo Maglina, Superficial Spreading, Nodular and Others Type
- Gender: Female and Male
- Treatment: Surgery, Radiation Therapy, Immunotherapy, Chemotherapy, Biologic Therapy and Others Treatment
- Diagnosis: Ugly Duckling, Biopsy, ABCDE and Other Diagnosis
- and End User: Clinics, Laboratories, Research Centers, Hospitals and Pharmaceutical Companies
- Regions: North America, Europe, Asia- Pacific, Latin America, Middle East & Africa
Industry Outlook
Melanoma is a type of cancer that is very dangerous, this cancer is developed when unrepaired DNA damage the skin cells triggering mutation, this in turn leads to multiplication of cells & develop into infectious tumors. Melanoma looks like a mole & sometimes develops from the mole. Primarily the Melanoma is black or brown in color, but can also be blue, white, red pink or skin-colored. Melanoma is caused by exposure of skin to UV rays. Melanoma is curable if detected & treated at the earlier stages. If not treated, it can spread to other parts of body making it hard to treat. Therefore, the Melanoma Market is anticipated to expand and has tremendous scope during the forecast period. The global Melanoma Market anticipated to flourish in the future by growing at a significantly higher CAGR.
Market Segmentation
The global Melanoma Market is based on segment, by Type the market is segmented into Acral Lentigious, Lentigo Maglina, Superficial Spreading, Nodular and Others Type, by Gender the market is segmented into Female and Male, by Treatment the market is segmented into Surgery, Radiation Therapy, Immunotherapy, Chemotherapy, Biologic Therapy and Others Treatment, by Diagnosis the market is segmented into Ugly Duckling, Biopsy, ABCDE and Other Diagnosis, and by End User the market is segmented into Clinics, Laboratories, Research Centers, Hospitals and Pharmaceutical Companies.
- Melanoma Market, By Type
- Acral Lentigious
- Lentigo Maglina
- Superficial Spreading
- Nodular
- Others Type
- Melanoma Market, By Gender
- Female
- Male
- Melanoma Market, By Treatment
- Surgery
- Radiation Therapy
- Immunotherapy
- Chemotherapy
- Biologic Therapy
- Others Treatment
- Melanoma Market, By Diagnosis
- Ugly Duckling
- Biopsy
- ABCDE
- Other Diagnosis
- Melanoma Market, By End User
- Clinics
- Laboratories
- Research Centers
- Hospitals
- Pharmaceutical Companies
Regional Insights
On a global front, the Melanoma Market covers North America (United States, Canada and Mexico), Europe (Germany, UK, France, Russia, Italy, Rest of Europe), Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific), South America (Brazil, Argentina, Columbia, Rest of South America) and Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA).
Melanoma Market, By Region
-
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Columbia
- Rest of South America
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Nigeria
- South Africa
- Rest of MEA
Competitive Analysis
The leading players in the market are Pfizer, Daiichi Sankyo Company Limited, Amgen, Inc., Novartis International AG., Merck & Co. Inc., Bristol-Myers Squibb, AstraZeneca, Eisai Co. Ltd., Ziopharm, F. Hoffmann-La Roche Ltd., Genentech Inc., Vical and Janssen Biotech Inc. The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and market share of the overall industry.
- Pfizer
- Daiichi Sankyo Company Limited
- Amgen Inc.
- Novartis International AG.
- Merck & Co. Inc.
- Bristol-Myers Squibb
- AstraZeneca
- Eisai Co. Ltd.
- Ziopharm
- F. Hoffmann-La Roche Ltd.
- Genentech Inc.
- Vical
- Janssen Biotech Inc.
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2017 to 2027?
- What will be the industry market growth from 2017 to 2027?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
o Melanoma Market, By Type, Estimates and Forecast, 2017-2027 ($Million)
o Acral Lentigious
o Lentigo Maglina
o Superficial Spreading
o Nodular
o Others Type
o Melanoma Market, By Gender, Estimates and Forecast, 2017-2027 ($Million)
o Female
o Male
o Melanoma Market, By Treatment, Estimates and Forecast, 2017-2027 ($Million)
o Surgery
o Radiation Therapy
o Immunotherapy
o Chemotherapy
o Biologic Therapy
o Others Treatment
o Melanoma Market, By Diagnosis, Estimates and Forecast, 2017-2027 ($Million)
o Ugly Duckling
o Biopsy
o ABCDE
o Other Diagnosis
o Melanoma Market, By End User, Estimates and Forecast, 2017-2027 ($Million)
o Clinics
o Laboratories
o Research Centers
o Hospitals
o Pharmaceutical Companies
Melanoma Market, By Region, Estimates and Forecast, 2017-2027 ($Million)
o North America
§ North America Melanoma Market, By Country
o U.S. Melanoma Market
o Canada Melanoma Market
o Mexico Melanoma Market
o Europe
§ Europe Melanoma Market, By Country
o Germany Melanoma Market
o UK Melanoma Market
o France Melanoma Market
o Russia Melanoma Market
o Italy Melanoma Market
o Rest of Europe Melanoma Market
o Asia-Pacific
§ Asia-Pacific Melanoma Market, By Country
o China Melanoma Market
o Japan Melanoma Market
o South Korea Melanoma Market
o India Melanoma Market
o Southeast Asia Melanoma Market
o Rest of Asia-Pacific Melanoma Market
o South America
§ South America Melanoma Market, By Country
o Brazil Melanoma Market
o Argentina Melanoma Market
o Columbia Melanoma Market
o Rest of South America Melanoma Market
o Middle East and Africa
§ Middle East and Africa Melanoma Market, By Country
o Saudi Arabia Melanoma Market
o UAE Melanoma Market
o Egypt Melanoma Market
o Nigeria Melanoma Market
o South Africa Melanoma Market
o Rest of MEA Melanoma Market
Table of Contents
1. Introduction
1.1. Report Description
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
3.3. SWOT Analysis
4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market Status and Outlook (2017-2027)
4.1.2. Canada Market Status and Outlook (2017-2027)
4.1.3. Mexico Market Status and Outlook (2017-2027)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market Status and Outlook (2017-2027)
4.2.2. France Market Status and Outlook (2017-2027)
4.2.3. UK Market Status and Outlook (2017-2027)
4.2.4. Russia Market Status and Outlook (2017-2027)
4.2.5. Italy Market Status and Outlook (2017-2027)
4.2.6. Rest of Europe Market Status and Outlook (2017-2027)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market Status and Outlook (2017-2027)
4.3.2. Japan Market Status and Outlook (2017-2027)
4.3.3. Korea Market Status and Outlook (2017-2027)
4.3.4. India Market Status and Outlook (2017-2027)
4.3.5. Southeast Asia Market Status and Outlook (2017-2027)
4.3.6. Rest of Asia-Pacific Market Status and Outlook (2017-2027)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market Status and Outlook (2017-2027)
4.4.2. Argentina Market Status and Outlook (2017-2027)
4.4.3. Columbia Market Status and Outlook (2017-2027)
4.4.4. Rest of South America Market Status and Outlook (2017-2027)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market Status and Outlook (2017-2027)
4.5.2. United Arab Emirates Market Status and Outlook (2017-2027)
4.5.3. Egypt Market Status and Outlook (2017-2027)
4.5.4. Nigeria Market Status and Outlook (2017-2027)
4.5.5. South Africa Market Status and Outlook (2017-2027)
4.5.6. Turkey Market Status and Outlook (2017-2027)
4.5.7. Rest of Middle East and Africa Market Status and Outlook (2017-2027)
5. Melanoma Market, By Type
5.1. Introduction
5.2. Global Melanoma Revenue and Market Share by Type (2017-2027)
5.2.1. Global Melanoma Revenue and Revenue Share by Type (2017-2027)
5.3. Acral Lentigious
5.3.1. Global Acral Lentigious Revenue and Growth Rate (2017-2027)
5.4. Lentigo Maglina
5.4.1. Global Lentigo Maglina Revenue and Growth Rate (2017-2027)
5.5. Superficial Spreading
5.5.1. Global Superficial Spreading Revenue and Growth Rate (2017-2027)
5.6. Nodular
5.6.1. Global Nodular Revenue and Growth Rate (2017-2027)
5.7. Others Type
5.7.1. Global Others Type Revenue and Growth Rate (2017-2027)
6. Melanoma Market, By Gender
6.1. Introduction
6.2. Global Melanoma Revenue and Market Share by Gender (2017-2027)
6.2.1. Global Melanoma Revenue and Revenue Share by Gender (2017-2027)
6.3. Female
6.3.1. Global Female Revenue and Growth Rate (2017-2027)
6.4. Male
6.4.1. Global Male Revenue and Growth Rate (2017-2027)
7. Melanoma Market, By Treatment
7.1. Introduction
7.2. Global Melanoma Revenue and Market Share by Treatment (2017-2027)
7.2.1. Global Melanoma Revenue and Revenue Share by Treatment (2017-2027)
7.3. Surgery
7.3.1. Global Surgery Revenue and Growth Rate (2017-2027)
7.4. Radiation Therapy
7.4.1. Global Radiation Therapy Revenue and Growth Rate (2017-2027)
7.5. Immunotherapy
7.5.1. Global Immunotherapy Revenue and Growth Rate (2017-2027)
7.6. Chemotherapy
7.6.1. Global Chemotherapy Revenue and Growth Rate (2017-2027)
7.7. Biologic Therapy
7.7.1. Global Biologic Therapy Revenue and Growth Rate (2017-2027)
7.8. Others Treatment
7.8.1. Global Others Treatment Revenue and Growth Rate (2017-2027)
8. Melanoma Market, By Diagnosis
8.1. Introduction
8.2. Global Melanoma Revenue and Market Share by Diagnosis (2017-2027)
8.2.1. Global Melanoma Revenue and Revenue Share by Diagnosis (2017-2027)
8.3. Ugly Duckling
8.3.1. Global Ugly Duckling Revenue and Growth Rate (2017-2027)
8.4. Biopsy
8.4.1. Global Biopsy Revenue and Growth Rate (2017-2027)
8.5. ABCDE
8.5.1. Global ABCDE Revenue and Growth Rate (2017-2027)
8.6. Other Diagnosis
8.6.1. Global Other Diagnosis Revenue and Growth Rate (2017-2027)
9. Melanoma Market, By End User
9.1. Introduction
9.2. Global Melanoma Revenue and Market Share by End User (2017-2027)
9.2.1. Global Melanoma Revenue and Revenue Share by End User (2017-2027)
9.3. Clinics
9.3.1. Global Clinics Revenue and Growth Rate (2017-2027)
9.4. Laboratories
9.4.1. Global Laboratories Revenue and Growth Rate (2017-2027)
9.5. Research Centers
9.5.1. Global Research Centers Revenue and Growth Rate (2017-2027)
9.6. Hospitals
9.6.1. Global Hospitals Revenue and Growth Rate (2017-2027)
9.7. Pharmaceutical Companies
9.7.1. Global Pharmaceutical Companies Revenue and Growth Rate (2017-2027)
10. Melanoma Market, By Region
10.1. Introduction
10.2. Global Melanoma Revenue and Market Share by Regions
10.2.1. Global Melanoma Revenue by Regions (2017-2027)
10.3. North America Melanoma by Countries
10.3.1. North America Melanoma Revenue and Growth Rate (2017-2027)
10.3.2. North America Melanoma Revenue (Million USD) by Countries (2017-2027)
10.3.3. United States
10.3.3.1. United States Melanoma Revenue (Millions USD) and Growth Rate (2017-2027)
10.3.4. Canada
10.3.4.1. Canada Melanoma Revenue (Millions USD) and Growth Rate (2017-2027)
10.3.5. Mexico
10.3.5.1. Mexico Melanoma Revenue (Millions USD) and Growth Rate (2017-2027)
10.4. Europe Melanoma by Countries
10.4.1. Europe Melanoma Revenue and Growth Rate (2017-2027)
10.4.2. Europe Melanoma Revenue (Million USD) by Countries (2017-2027)
10.4.3. Germany
10.4.3.1. Germany Melanoma Revenue (Millions USD) and Growth Rate (2017-2027)
10.4.4. France
10.4.4.1. France Melanoma Revenue (Millions USD) and Growth Rate (2017-2027)
10.4.5. UK
10.4.5.1. UK Melanoma Revenue (Millions USD) and Growth Rate (2017-2027)
10.4.6. Russia
10.4.6.1. Russia Melanoma Revenue (Millions USD) and Growth Rate (2017-2027)
10.4.7. Italy
10.4.7.1. Italy Melanoma Revenue (Millions USD) and Growth Rate (2017-2027)
10.4.8. Rest of Europe
10.4.8.1. Rest of Europe Melanoma Revenue (Millions USD) and Growth Rate (2017-2027)
10.5. Asia-Pacific Melanoma by Countries
10.5.1. Asia-Pacific Melanoma Revenue and Growth Rate (2017-2027)
10.5.2. Asia-Pacific Melanoma Revenue (Million USD) by Countries (2017-2027)
10.5.3. China
10.5.3.1. China Melanoma Revenue (Millions USD) and Growth Rate (2017-2027)
10.5.4. Japan
10.5.4.1. Japan Melanoma Revenue (Millions USD) and Growth Rate (2017-2027)
10.5.5. Korea
10.5.5.1. Korea Melanoma Revenue (Millions USD) and Growth Rate (2017-2027)
10.5.6. India
10.5.6.1. India Melanoma Revenue (Millions USD) and Growth Rate (2017-2027)
10.5.7. Southeast Asia
10.5.7.1. Southeast Asia Melanoma Revenue (Millions USD) and Growth Rate (2017-2027)
10.5.8. Rest of Asia-Pacific
10.5.8.1. Rest of Asia-Pacific Melanoma Revenue (Millions USD) and Growth Rate (2017-2027)
10.6. South America Melanoma by Countries
10.6.1. South America Melanoma Revenue and Growth Rate (2017-2027)
10.6.2. South America Melanoma Revenue (Million USD) by Countries (2017-2027)
10.6.3. Brazil
10.6.3.1. Brazil Melanoma Revenue (Millions USD) and Growth Rate (2017-2027)
10.6.4. Argentina
10.6.4.1. Argentina Melanoma Revenue (Millions USD) and Growth Rate (2017-2027)
10.6.5. Columbia
10.6.5.1. Columbia Melanoma Revenue (Millions USD) and Growth Rate (2017-2027)
10.6.6. Rest of South America
10.6.6.1. Rest of South America Melanoma Revenue (Millions USD) and Growth Rate (2017-2027)
10.7. Middle East and Africa Melanoma by Countries
10.7.1. Middle East and Africa Melanoma Revenue and Growth Rate (2017-2027)
10.7.2. Middle East and Africa Melanoma Revenue (Million USD) by Countries (2017-2027)
10.7.3. Saudi Arabia
10.7.3.1. Saudi Arabia Melanoma Revenue (Millions USD) and Growth Rate (2017-2027)
10.7.4. United Arab Emirates
10.7.4.1. United Arab Emirates Melanoma Revenue (Millions USD) and Growth Rate (2017-2027)
10.7.5. Egypt
10.7.5.1. Egypt Melanoma Revenue (Millions USD) and Growth Rate (2017-2027)
10.7.6. Nigeria
10.7.6.1. Nigeria Melanoma Revenue (Millions USD) and Growth Rate (2017-2027)
10.7.7. South Africa
10.7.7.1. South Africa Melanoma Revenue (Millions USD) and Growth Rate (2017-2027)
10.7.8. Turkey
10.7.8.1. Turkey Melanoma Revenue (Millions USD) and Growth Rate (2017-2027)
10.7.9. Rest of Middle East and Africa
10.7.9.1. Rest of Middle East and Africa Melanoma Revenue (Millions USD) and Growth Rate (2017-2027)
11. Company Profiles
11.1. Pfizer
11.1.1. Business Overview
11.1.2. Service Portfolio
11.1.3. Strategic Developments
11.1.4. Revenue and Market Share
11.2. Daiichi Sankyo Company Limited
11.2.1. Business Overview
11.2.2. Service Portfolio
11.2.3. Strategic Developments
11.2.4. Revenue and Market Share
11.3. Amgen Inc.
11.3.1. Business Overview
11.3.2. Service Portfolio
11.3.3. Strategic Developments
11.3.4. Revenue and Market Share
11.4. Novartis International AG.
11.4.1. Business Overview
11.4.2. Service Portfolio
11.4.3. Strategic Developments
11.4.4. Revenue and Market Share
11.5. Merck & Co. Inc.
11.5.1. Business Overview
11.5.2. Service Portfolio
11.5.3. Strategic Developments
11.5.4. Revenue and Market Share
11.6. Bristol-Myers Squibb
11.6.1. Business Overview
11.6.2. Service Portfolio
11.6.3. Strategic Developments
11.6.4. Revenue and Market Share
11.7. AstraZeneca
11.7.1. Business Overview
11.7.2. Service Portfolio
11.7.3. Strategic Developments
11.7.4. Revenue and Market Share
11.8. Eisai Co. Ltd.
11.8.1. Business Overview
11.8.2. Service Portfolio
11.8.3. Strategic Developments
11.8.4. Revenue and Market Share
11.9. Ziopharm
11.9.1. Business Overview
11.9.2. Service Portfolio
11.9.3. Strategic Developments
11.9.4. Revenue and Market Share
11.10. F. Hoffmann-La Roche Ltd.
11.10.1. Business Overview
11.10.2. Service Portfolio
11.10.3. Strategic Developments
11.10.4. Revenue and Market Share
11.11. Genentech Inc.
11.11.1. Business Overview
11.11.2. Service Portfolio
11.11.3. Strategic Developments
11.11.4. Revenue and Market Share
11.12. Vical
11.12.1. Business Overview
11.12.2. Service Portfolio
11.12.3. Strategic Developments
11.12.4. Revenue and Market Share
11.13. Janssen Biotech Inc.
11.13.1. Business Overview
11.13.2. Service Portfolio
11.13.3. Strategic Developments
11.13.4. Revenue and Market Share
12. Global Melanoma Market Competition, by Manufacturer
12.1. Global Melanoma Revenue and Market Share by Manufacturer (2017-2017)
12.2. Global Melanoma Price By Region (2017-2017)
12.3. Top 5 Melanoma Manufacturer Market Share
12.4. Market Competition Trend
13. Melanoma Market Forecast (2017-2027)
13.1. Global Melanoma Revenue (Millions USD) and Growth Rate (2017-2027)
13.2. Melanoma Market Forecast by Regions (2017-2027)
13.2.1. North America Melanoma Market Forecast (2017-2027)
13.2.1.1. United States Melanoma Market Forecast (2017-2027)
13.2.1.2. Canada Melanoma Market Forecast (2017-2027)
13.2.1.3. Mexico Melanoma Market Forecast (2017-2027)
13.2.2. Europe Melanoma Market Forecast (2017-2027)
13.2.2.1. Germany Melanoma Market Forecast (2017-2027)
13.2.2.2. France Melanoma Market Forecast (2017-2027)
13.2.2.3. UK Melanoma Market Forecast (2017-2027)
13.2.2.4. Russia Melanoma Market Forecast (2017-2027)
13.2.2.5. Italy Melanoma Market Forecast (2017-2027)
13.2.2.6. Rest of Europe Melanoma Market Forecast (2017-2027)
13.2.3. Asia-Pacific Melanoma Market Forecast (2017-2027)
13.2.3.1. China Melanoma Market Forecast (2017-2027)
13.2.3.2. Japan Melanoma Market Forecast (2017-2027)
13.2.3.3. Korea Melanoma Market Forecast (2017-2027)
13.2.3.4. India Melanoma Market Forecast (2017-2027)
13.2.3.5. Southeast Asia Melanoma Market Forecast (2017-2027)
13.2.3.6. Rest of Asia-Pacific Melanoma Market Forecast (2017-2027)
13.2.4. South America Melanoma Market Forecast (2017-2027)
13.2.4.1. Brazil Melanoma Market Forecast (2017-2027)
13.2.4.2. Argentina Melanoma Market Forecast (2017-2027)
13.2.4.3. Columbia Melanoma Market Forecast (2017-2027)
13.2.4.4. Rest of South America Melanoma Market Forecast (2017-2027)
13.2.5. Middle East and Africa Melanoma Market Forecast (2017-2027)
13.2.5.1. Saudi Arabia Melanoma Market Forecast (2017-2027)
13.2.5.2. United Arab Emirates Melanoma Market Forecast (2017-2027)
13.2.5.3. Egypt Melanoma Market Forecast (2017-2027)
13.2.5.4. Nigeria Melanoma Market Forecast (2017-2027)
13.2.5.5. South Africa Melanoma Market Forecast (2017-2027)
13.2.5.6. Turkey Melanoma Market Forecast (2017-2027)
13.2.5.7. Rest of Middle East and Africa Melanoma Market Forecast (2017-2027)
13.3. Melanoma Market Forecast by Type (2017-2027)
13.3.1. Melanoma Forecast by Type (2017-2027)
13.3.2. Melanoma Market Share Forecast by Type (2017-2027)
13.4. Melanoma Market Forecast by Gender (2017-2027)
13.4.1. Melanoma Forecast by Gender (2017-2027)
13.4.2. Melanoma Market Share Forecast by Gender (2017-2027)
13.5. Melanoma Market Forecast by Treatment (2017-2027)
13.5.1. Melanoma Forecast by Treatment (2017-2027)
13.5.2. Melanoma Market Share Forecast by Treatment (2017-2027)
13.6. Melanoma Market Forecast by Diagnosis (2017-2027)
13.6.1. Melanoma Forecast by Diagnosis (2017-2027)
13.6.2. Melanoma Market Share Forecast by Diagnosis (2017-2027)
13.7. Melanoma Market Forecast by End User (2017-2027)
13.7.1. Melanoma Forecast by End User (2017-2027)
13.7.2. Melanoma Market Share Forecast by End User (2017-2027)
List of Tables
14. List of Tables and Figures
Figure United States Melanoma Revenue (Million USD) and Growth Rate (2017-2025)
Figure Canada Melanoma Revenue (Million USD) and Growth Rate (2017-2025)
Figure Mexico Melanoma Revenue (Million USD) and Growth Rate (2017-2025)
Figure Germany Melanoma Revenue (Million USD) and Growth Rate (2017-2025)
Figure France Melanoma Revenue (Million USD) and Growth Rate (2017-2025)
Figure UK Melanoma Revenue (Million USD) and Growth Rate (2017-2025)
Figure Russia Melanoma Revenue (Million USD) and Growth Rate (2017-2025)
Figure Italy Melanoma Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Europe Melanoma Revenue (Million USD) and Growth Rate (2017-2025)
Figure China Melanoma Revenue (Million USD) and Growth Rate (2017-2025)
Figure Japan Melanoma Revenue (Million USD) and Growth Rate (2017-2025)
Figure Korea Melanoma Revenue (Million USD) and Growth Rate (2017-2025)
Figure India Melanoma Revenue (Million USD) and Growth Rate (2017-2025)
Figure Southeast Asia Melanoma Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Asia-Pacific Melanoma Revenue (Million USD) and Growth Rate (2017-2025)
Figure Brazil Melanoma Revenue (Million USD) and Growth Rate (2017-2025)
Figure Argentina Melanoma Revenue (Million USD) and Growth Rate (2017-2025)
Figure Columbia Melanoma Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of South America Melanoma Revenue (Million USD) and Growth Rate (2017-2025)
Figure Saudi Arabia Melanoma Revenue (Million USD) and Growth Rate (2017-2025)
Figure United Arab Emirates Melanoma Revenue (Million USD) and Growth Rate (2017-2025)
Figure Egypt Melanoma Revenue (Million USD) and Growth Rate (2017-2025)
Figure Nigeria Melanoma Revenue (Million USD) and Growth Rate (2017-2025)
Figure South Africa Melanoma Revenue (Million USD) and Growth Rate (2017-2025)
Figure Turkey Melanoma Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Middle East and Africa Melanoma Revenue (Million USD) and Growth Rate (2017-2025)
Table Global Melanoma Revenue and Revenue Share by Type (2017-2018)
Figure Global Acral Lentigious Revenue and Growth Rate (2017-2018)
Figure Global Lentigo Maglina Revenue and Growth Rate (2017-2018)
Figure Global Superficial Spreading Revenue and Growth Rate (2017-2018)
Figure Global Nodular Revenue and Growth Rate (2017-2018)
Figure Global Others Type Revenue and Growth Rate (2017-2018)
Table Global Melanoma Revenue and Revenue Share by Gender (2017-2018)
Figure Global Female Revenue and Growth Rate (2017-2018)
Figure Global Male Revenue and Growth Rate (2017-2018)
Table Global Melanoma Revenue and Revenue Share by Treatment (2017-2018)
Figure Global Surgery Revenue and Growth Rate (2017-2018)
Figure Global Radiation Therapy Revenue and Growth Rate (2017-2018)
Figure Global Immunotherapy Revenue and Growth Rate (2017-2018)
Figure Global Chemotherapy Revenue and Growth Rate (2017-2018)
Figure Global Biologic Therapy Revenue and Growth Rate (2017-2018)
Figure Global Others Treatment Revenue and Growth Rate (2017-2018)
Table Global Melanoma Revenue and Revenue Share by Diagnosis (2017-2018)
Figure Global Ugly Duckling Revenue and Growth Rate (2017-2018)
Figure Global Biopsy Revenue and Growth Rate (2017-2018)
Figure Global ABCDE Revenue and Growth Rate (2017-2018)
Figure Global Other Diagnosis Revenue and Growth Rate (2017-2018)
Table Global Melanoma Revenue and Revenue Share by End User (2017-2018)
Figure Global Clinics Revenue and Growth Rate (2017-2018)
Figure Global Laboratories Revenue and Growth Rate (2017-2018)
Figure Global Research Centers Revenue and Growth Rate (2017-2018)
Figure Global Hospitals Revenue and Growth Rate (2017-2018)
Figure Global Pharmaceutical Companies Revenue and Growth Rate (2017-2018)
Table Global Melanoma Revenue by Regions (2017-2018)
Figure North America Melanoma Growth Rate (2017-2018)
Figure North America Melanoma Revenue and Growth Rate (2017-2018)
Figure North America Melanoma by Countries (2017-2018)
Figure North America Melanoma Revenue (Million USD) by Countries (2017-2018)
Figure United States Melanoma Growth Rate (2017-2018)
Figure United States Melanoma Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Canada Melanoma Growth Rate (2017-2018)
Figure Canada Melanoma Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Mexico Melanoma Growth Rate (2017-2018)
Figure Mexico Melanoma Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Europe Melanoma Growth Rate (2017-2018)
Figure Europe Melanoma Revenue and Growth Rate (2017-2018)
Figure Europe Melanoma by Countries (2017-2018)
Figure Europe Melanoma Revenue (Million USD) by Countries (2017-2018)
Figure Germany Melanoma Growth Rate (2017-2018)
Figure Germany Melanoma Revenue (Millions USD) and Growth Rate (2017-2018)
Figure France Melanoma Growth Rate (2017-2018)
Figure France Melanoma Revenue (Millions USD) and Growth Rate (2017-2018)
Figure UK Melanoma Growth Rate (2017-2018)
Figure UK Melanoma Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Russia Melanoma Growth Rate (2017-2018)
Figure Russia Melanoma Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Italy Melanoma Growth Rate (2017-2018)
Figure Italy Melanoma Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Europe Melanoma Growth Rate (2017-2018)
Figure Rest of Europe Melanoma Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Asia-Pacific Melanoma Growth Rate (2017-2018)
Figure Asia-Pacific Melanoma Revenue and Growth Rate (2017-2018)
Figure Asia-Pacific Melanoma by Countries (2017-2018)
Figure Asia-Pacific Melanoma Revenue (Million USD) by Countries (2017-2018)
Figure China Melanoma Growth Rate (2017-2018)
Figure China Melanoma Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Japan Melanoma Growth Rate (2017-2018)
Figure Japan Melanoma Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Korea Melanoma Growth Rate (2017-2018)
Figure Korea Melanoma Revenue (Millions USD) and Growth Rate (2017-2018)
Figure India Melanoma Growth Rate (2017-2018)
Figure India Melanoma Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Southeast Asia Melanoma Growth Rate (2017-2018)
Figure Southeast Asia Melanoma Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Melanoma Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Melanoma Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South America Melanoma Growth Rate (2017-2018)
Figure South America Melanoma Revenue and Growth Rate (2017-2018)
Figure South America Melanoma by Countries (2017-2018)
Figure South America Melanoma Revenue (Million USD) by Countries (2017-2018)
Figure Brazil Melanoma Growth Rate (2017-2018)
Figure Brazil Melanoma Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Argentina Melanoma Growth Rate (2017-2018)
Figure Argentina Melanoma Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Columbia Melanoma Growth Rate (2017-2018)
Figure Columbia Melanoma Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of South America Melanoma Growth Rate (2017-2018)
Figure Rest of South America Melanoma Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Middle East and Africa Melanoma Growth Rate (2017-2018)
Figure Middle East and Africa Melanoma Revenue and Growth Rate (2017-2018)
Figure Middle East and Africa Melanoma by Countries (2017-2018)
Figure Middle East and Africa Melanoma Revenue (Million USD) by Countries (2017-2018)
Figure Saudi Arabia Melanoma Growth Rate (2017-2018)
Figure Saudi Arabia Melanoma Revenue (Millions USD) and Growth Rate (2017-2018)
Figure United Arab Emirates Melanoma Growth Rate (2017-2018)
Figure United Arab Emirates Melanoma Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Egypt Melanoma Growth Rate (2017-2018)
Figure Egypt Melanoma Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Nigeria Melanoma Growth Rate (2017-2018)
Figure Nigeria Melanoma Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South Africa Melanoma Growth Rate (2017-2018)
Figure South Africa Melanoma Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Turkey Melanoma Growth Rate (2017-2018)
Figure Turkey Melanoma Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Melanoma Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Melanoma Revenue (Millions USD) and Growth Rate (2017-2018)
Table Pfizer Melanoma Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Daiichi Sankyo Company Limited Melanoma Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Amgen Inc. Melanoma Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Novartis International AG. Melanoma Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Merck & Co. Inc. Melanoma Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Bristol-Myers Squibb Melanoma Price, Revenue, Gross Margin and Market Share (2017-2017)
Table AstraZeneca Melanoma Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Eisai Co. Ltd. Melanoma Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Ziopharm Melanoma Price, Revenue, Gross Margin and Market Share (2017-2017)
Table F. Hoffmann-La Roche Ltd. Melanoma Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Genentech Inc. Melanoma Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Vical Melanoma Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Janssen Biotech Inc. Melanoma Price, Revenue, Gross Margin and Market Share (2017-2017)
Figure Global Melanoma Market Share by Manufacturer
Figure Global Melanoma Revenue and Market Share by Manufacturer
Table Global Melanoma Price by Region (2017-2017)
Figure Top 5 Melanoma Manufacturer (Revenue) Market Share
Figure Market Competition Trend
Figure Global Melanoma Revenue (Millions USD) and Growth Rate (2018-2025)
Table Melanoma Market Forecast by Regions (2018-2025)
Figure North America Melanoma Market Forecast (2018-2025)
Figure United States Melanoma Market Forecast (2018-2025)
Figure Canada Melanoma Market Forecast (2018-2025)
Figure Mexico Melanoma Market Forecast (2018-2025)
Figure Europe Melanoma Market Forecast (2018-2025)
Figure Germany Melanoma Market Forecast (2018-2025)
Figure France Melanoma Market Forecast (2018-2025)
Figure UK Melanoma Market Forecast (2018-2025)
Figure Russia Melanoma Market Forecast (2018-2025)
Figure Italy Melanoma Market Forecast (2018-2025)
Figure Rest of Europe Melanoma Market Forecast (2018-2025)
Figure Asia-Pacific Melanoma Market Forecast (2018-2025)
Figure China Melanoma Market Forecast (2018-2025)
Figure Japan Melanoma Market Forecast (2018-2025)
Figure Korea Melanoma Market Forecast (2018-2025)
Figure India Melanoma Market Forecast (2018-2025)
Figure Southeast Asia Melanoma Market Forecast (2018-2025)
Figure Rest of Asia-Pacific Melanoma Market Forecast (2018-2025)
Figure South America Melanoma Market Forecast (2018-2025)
Figure Brazil Melanoma Market Forecast (2018-2025)
Figure Argentina Melanoma Market Forecast (2018-2025)
Figure Columbia Melanoma Market Forecast (2018-2025)
Figure Rest of South America Melanoma Market Forecast (2018-2025)
Figure Middle East and Africa Melanoma Market Forecast (2018-2025)
Figure Saudi Arabia Melanoma Market Forecast (2018-2025)
Figure United Arab Emirates Melanoma Market Forecast (2018-2025)
Figure Egypt Melanoma Market Forecast (2018-2025)
Figure Nigeria Melanoma Market Forecast (2018-2025)
Figure South Africa Melanoma Market Forecast (2018-2025)
Figure Turkey Melanoma Market Forecast (2018-2025)
Figure Rest of Middle East and Africa Melanoma Market Forecast (2018-2025)
Figure Global Melanoma Forecast by Type (2018-2025)
Figure Global Melanoma Market Share Forecast by Type (2018-2025)
Figure Global Melanoma Forecast by Type (2018-2025)
Figure Global Melanoma Forecast by Gender (2018-2025)
Figure Global Melanoma Market Share Forecast by Gender (2018-2025)
Figure Global Melanoma Forecast by Gender (2018-2025)
Figure Global Melanoma Forecast by Treatment (2018-2025)
Figure Global Melanoma Market Share Forecast by Treatment (2018-2025)
Figure Global Melanoma Forecast by Treatment (2018-2025)
Figure Global Melanoma Forecast by Diagnosis (2018-2025)
Figure Global Melanoma Market Share Forecast by Diagnosis (2018-2025)
Figure Global Melanoma Forecast by Diagnosis (2018-2025)
Figure Global Melanoma Forecast by End User (2018-2025)
Figure Global Melanoma Market Share Forecast by End User (2018-2025)
Figure Global Melanoma Forecast by End User (2018-2025)
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|